In recent years many of the cutting-edge inventions in the life science industry went by unnoticed. Everybody pops a pill once in a while without knowing how much effort has been put behind it.

Since the pandemic, more and more people got interested in

• public health,

• drug development,

• virology and

• many other disciplines necessary to bring a new vaccine or drug to the patients.

The life science industry showed that with increased collaboration, a novel vaccine could be developed from the lab bench to market within 12 months only. A process that previously took more than five to ten years for development work only.

What other technologies are in development worth looking further into?

The Genomics Revolution

In 2014, Cathie Wood started Ark Invest, which manages ETFs based on what she calls disruptive Platforms of Innovation.

In the Big Ideas Reports 2017, 2018, 2019, 2020, and 2021 she highlighted those Platforms and presented the most recent developments in these fields every year.

One of those 5 Platforms of Innovation is the Genomics Revolution. Her fund invests in companies that are moving innovation forward in these areas:

• CRISPR

• Targeted Therapeutics

• Bioinformatics

• Molecular Diagnostics

• Stem Cells

• Agricultural Biology

Since its inception, the companies in the ARK Genomics Revolution ETF delivered a return of almost 30 percent each year. This is roughly three times the average annual return of an S&P 500 ETF.

Aelian Biotechnology

It is about time to shine a light on these hot topics in the LSG2G Podcast series. One of the European hotspots of Gene Editing is in Vienna.

Aelian Biotechnology is one of the companies that are positioned in this field. The company combines CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes.

It utilizes the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens.

The powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs.

I am thrilled to have the opportunity to chat with the founders

• Tilmann Buerckstuemmer and

• Thomas Moser

about the past, present, and future of the Genomics Revolution.

In this episode, we will cover questions like:
- How to create a novel life science company focusing on Gene Editing.
- What is Gene Editing?
- Why is there so much excitement around Genomics, CRISPR, and Gene Sequencing?
- Where does it all come from?
- What developments are already in the pipeline that will change society?

Join us the get more insights into the secrets of Gene Editing:

Register Now

Noteworthy Articles:

Ping An Makes Breakthrough in Artificial Intelligence-Driven Drug Research The findings were published in "An effective self-supervised framework for learning expressive molecular global representations to drug discovery" in Briefings in Bioinformatics, a peer-reviewed bioinformatics journal. It marks a major technology breakthrough for the Group in the field of AI-driven pharmaceutical research. Read more…

Transmit Security Becomes Cyber’s Latest Unicorn After $543M Series A, Israel-based Transmit Security hit a pre-money valuation of $2.3 billion after raising a $543 million Series A. Read more…

Visa, PayPal Join Crypto VC Blockchain Capital’s New $300M Fund: PayPal and Visa are chasing bets across the crypto industry as partners in Blockchain Capital’s fifth venture fund, a $300 million war chest announced Tuesday. The increasingly crypto-savvy companies are relative newcomers to crypto VC. While both have invested directly in a handful of crypto startups, joining as limited partners (LPs) means an outside manager will place broader equity investments on their behalf. PayPal confirmed to CoinDesk this is its first such arrangement with a crypto VC firm. Read more…

LISTEN TO THIS EPISODE OF THE LSG2G PODCAST HERE

At the beginning of the new millennium, the next technological quantum leap began to emerge, known as the fourth industrial revolution – or Industry 4.0 for short. New technologies permit the development of new business models. In general, a business model describes a company’s business processes to achieve a defined business objective within the context of its social environment. The term sums up visions, ideas, defining features, and design models.

In the context of digitization, intellectual property (IP) is becoming an increasingly important element in a company’s strategy to remain competitive by establishing defensible positions. This importance necessitates systematic and value-driven management of IP. In light of the shift from a production-oriented towards a software-driven economy, finding valuable ideas has become challenging. The formation of digitalized eco-systems allows new market entrants to compete with established companies easily. Therefore, understanding how intellectual property rights can protect aspects of such digital business models is desirable.

LISTEN TO THIS EPISODE OF THE LSG2G PODCAST HERE

Community Partner:

These companies make the community, this newsletter, and the LSG2G Podcast possible, so go check them out and thank them for their support!

Partner Links

You are receiving the LSG2G-Letter because you either signed up or attended one of the events organized by LSG2G. Feel free to unsubscribe if you aren’t finding this valuable.

Nothing in this email is intended to serve as financial advice. Do your own research.